Recombinetics Inc.
- UEI
- L99NWZNZ7K57
- CAGE
- 5ECE0
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- recombinetics.com
- Founded
- 2008
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Production of two gene-edited angus fibroblast primary cell linesper the technical requirements (CD46, 6AA swap) (947) | Plains Area (FRIID) | $30,050 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Recombinetics Inc. is a corporate entity registered in SAM.gov since 2009, specializing in advanced biotechnology and genetic engineering research. Located in Eagan, Minnesota, the company appears to focus on gene editing, cellular research, and developing innovative therapeutic approaches for rare genetic diseases. While not currently holding a federal contract vehicle, Recombinetics has successfully received federal grant awards that demonstrate its sophisticated scientific capabilities in genetic research and modeling.
The company's federal contract award history shows limited engagement, with one specific contract for the production of gene-edited Angus fibroblast primary cell lines. This $30,050 purchase order was awarded on February 8, 2022, with completion by August 8, 2022, and was issued through the Plains Area agency. The contract did not involve any specific set-aside designation and represents a specialized cellular research procurement.
Recombinetics has been more extensively involved in federal grant research, with two significant project grants from major federal agencies. The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a $228,863 grant focusing on gene therapy for Mucopolysaccharidosis Type IVA, involving the development of a porcine disease model and exploring innovative gene therapy approaches. Additionally, the National Cancer Institute provided funding for a $300,000 grant to develop an inducible swine hepatocellular carcinoma platform, aiming to create advanced preclinical models for cancer therapeutic development. These grants demonstrate Recombinetics' expertise in developing sophisticated animal models for understanding complex genetic diseases and potential therapeutic interventions, with a particular focus on translational research that bridges laboratory findings to potential clinical applications.
Quick answers
Is Recombinetics Inc. registered in SAM.gov?
Recombinetics Inc.'s SAM.gov registration expired on August 6, 2025.
What is Recombinetics Inc.'s most recent federal award?
Recombinetics Inc.'s most recent federal grant award is Gene therapy for MPS IV a in a novel porcine model of the disease (R43AR084639), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases (NIH), on September 18, 2024.
On GovTribe
See Recombinetics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors